Dyne Therapeutics (DYN) Research & Development (2019 - 2026)

Dyne Therapeutics (DYN) has 8 years of Research & Development data on file, last reported at $100.9 million in Q1 2026.

• On a quarterly basis, Research & Development fell 5.22% year-over-year to $100.9 million in Q1 2026; TTM through Mar 2026 was $392.8 million, a 14.41% increase from a year earlier, with the FY2025 full-year figure at $398.3 million, up 41.55% from the prior year.
• Research & Development for Q1 2026 stood at $100.9 million, up from $95.4 million in the prior quarter.
• Over the last five years, Research & Development for DYN reached as high as $106.4 million in Q1 2025 and fell as low as $28.2 million in Q1 2022.
• Historically, Research & Development has averaged $66.7 million across 5 years, with a median of $59.1 million in 2023.
• Across the five-year window, Research & Development declined 21.54% in 2022 and soared 139.0% in 2025, its largest moves.
• Year by year, Research & Development stood at $33.2 million in 2022, then jumped by 77.29% to $58.8 million in 2023, then jumped by 39.02% to $81.8 million in 2024, then grew by 16.66% to $95.4 million in 2025, then climbed by 5.72% to $100.9 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $100.9 million in Q1 2026, $95.4 million in Q4 2025, and $97.2 million in Q3 2025.